A5089401386- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Occupational and environmental lung diseases
- Melanoma and MAPK Pathways
- COVID-19 Clinical Research Studies
- Medical Imaging and Pathology Studies
- Ocular Oncology and Treatments
- COVID-19 and healthcare impacts
- Cancer-related Molecular Pathways
- Autoimmune Neurological Disorders and Treatments
- Inflammasome and immune disorders
- Glaucoma and retinal disorders
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Chemotherapy-related skin toxicity
- Polyomavirus and related diseases
- Infection Control and Ventilation
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Brain Metastases and Treatment
- Sarcoidosis and Beryllium Toxicity Research
Hôpital Nord
2021-2024
Aix-Marseille Université
2024
Université Paris Cité
2017-2022
Université Claude Bernard Lyon 1
2017-2022
Assistance Publique – Hôpitaux de Paris
2017-2022
Inserm
2018-2022
Hôpital Bichat-Claude-Bernard
2017-2022
Délégation Paris 7
2017-2021
Assistance Publique Hôpitaux de Marseille
2021
Centre Hospitalier Saint-Denis
2019
<h3>Background</h3> Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients a PNS. Our objective was to describe the outcome for pre-existing newly diagnosed PNS following initiation of immunotherapy. <h3>Methods</h3> We included all adult (aged ≥18) treated solid tumor, PNS, and registered French pharmacovigilance databases. Patients were allocated cohorts 1 2 if had been before vs....
Background The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. Material methods A cohort study was designed to evaluate whether a therapeutic algorithm using steroids or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients ≥5-day evolution since symptoms onset, (CRP≥50mg/L), requiring 3–5 L/min oxygen, received methylprednisolone alone. needing ≥6 + subcutaneous anakinra daily...
Abstract Background Choroidal metastases are the most common eye metastatic site. The prevalence of choroidal in NSCLC patients has been reported to vary from 0.2 7% historical series. Although previously reported, little is known about metastasis Epidermal Growth Factor Receptor (EGFR)-mutant Non-small cell lung cancer (NSCLC). This study sought describe among with EGFR-mutated and their characteristics, estimate impact on prognosis. Methods We conducted a single-center retrospective...
Disseminated Histoplasmosis (DH) is a rare manifestation of Acquired Immune Deficiency Syndrome (AIDS) in European countries. Naso-maxillar osteolysis due to Histoplasma capsulatum var. (Hcc) unusual endemic countries and has never been reported Differential diagnoses such as malignant tumors, cocaine use, granulomatosis, vasculitis infections are more frequently observed could delay and/or bias the final diagnosis. We report case an immunocompromised patient infected by Human...
Sporadic lymphangioleiomyomatosis (LAM) is a rare form of diffuse parenchymal lung disease. PD-1 blocking antibodies constitute an essential treatment option for advanced non-small-cell cancer (NSCLC). The effect immune checkpoint inhibitors in patients with non-small cell unknown: concomitant symptomatic interstitial disease or the use immunosuppressors was key exclusion criterion original studies inhibitors, especially regarding risk exacerbation. A 48-year-old female, active smoker (36...
<b><i>ERBB4</i> fusion is a rare, novel oncogenic event involved in the development of lung adenocarcinoma that not routinely looked for, although <i>ERBB4</i> potential target for existing pan-ErbB tyrosine kinase and must be implemented laboratory</b>https://bit.ly/3nYmGQ9
Walking speed (WS) has emerged as a potential predictor of mortality in elderly cancer patients, yet data involving non-small-cell lung (NSCLC) patients are scarce. Our prospective exploratory study sought to determine whether WS would predict early death or toxicity with advanced NSCLC receiving first-line systemic intravenous treatment. Overall, 145 ≥70 years were diagnosed over 19 months, 91 whom displayed locally-advanced metastatic cancer. As treatment, 21 (23%) received best supportive...
Interstitial lung disease (ILD) is a known risk factor for cancer (LC). However, the surgical of LC in patients with ILD remains unclear. Therefore, we conducted single-center retrospective study to assess clinical features and outcome population who underwent surgery or without ILD. Patients between January 2006 June 2023 our center were assessed using data extracted from nationwide Epithor thoracic database. Suspicion was based on patients' records. Confirmation then made patient's medical...
Background: Prophylactic cranial irradiation (PCI) is recommended to decrease the incidence of brain metastases (BM) in extensive-stage small-cell lung cancer (ESSCLC) without BM after response chemotherapy. However, PCI associated with significant neurocognitive effects, and new studies are debating its benefits. Moreover, introduction immunotherapy management disease has raised questions, there a lack data on immunotherapy. We report single-center retrospective study evaluating impact...
Background: Tumor mutational burden (TMB) correlates with response to immune checkpoint inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that TP53 mutations could reflect TMB and predict ICI benefit. Methods: were assessed by next-generation sequencing aNSCLC patients treated programmed death-1 (PD-1) blockers. Clinical data, tumor death ligand-1 (PD-L1) expression, KRAS status collected. The primary endpoint was overall survival (OS). Results: In total, 72...